Emergent Biosolutions
EBS
EBS
232 hedge funds and large institutions have $1.28B invested in Emergent Biosolutions in 2022 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 64 increasing their positions, 102 reducing their positions, and 38 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less ownership
Funds ownership: →
less funds holding
Funds holding: →
26% less capital invested
Capital invested by funds: $1.72B → $1.28B (-$438M)
37% less repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 102
45% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 38
Holders
232
Holding in Top 10
1
Calls
$5.37M
Puts
$1.52M
Top Buyers
| 1 | +$21.1M | |
| 2 | +$18.1M | |
| 3 | +$18M | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$13.9M |
| 5 |
Morgan Stanley
New York
|
+$8.15M |
Top Sellers
| 1 | -$22.4M | |
| 2 | -$9.66M | |
| 3 | -$8.57M | |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$8.52M |
| 5 |
SCM
Snyder Capital Management
San Francisco,
California
|
-$8.39M |